secwatch.observer — SEC 8-K summary
======================================

Issuer:     BIOCRYST PHARMACEUTICALS INC (BCRX)
CIK:        0000882796
Form:       8-K
Filed at:   2023-11-03T23:59:59+00:00
Accession:  0001171843-23-006716
Event type: other_material
Sentiment:  positive
Materiality: 0.65
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

BioCryst and Clearside partner to develop avoralstat for DME via SCS Microinjector; $5M upfront
--------------------------------------------------------------------------------

- License agreement for avoralstat for diabetic macular edema using Clearside's SCS Microinjector.
- BioCryst pays $5M upfront; Clearside eligible for up to $30M in clinical/regulatory milestones and up to $47.5M in sales milestones.
- Avoralstat previously safe in Phase 3 HAE trial; high potency and low solubility suited for suprachoroidal delivery.
- DME is common cause of vision loss; one-third of patients don't respond to anti-VEGF therapies.
- BioCryst to host R&D Day today at 1:00 pm ET.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/882796/000117184323006716/0001171843-23-006716-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/882796/000117184323006716/f8k_110323.htm
  HTML page:      https://secwatch.observer/filing/0001171843-23-006716

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer